Drug-resistant virus has reduced ability to induce immune activation.
作者信息
Wang Rui, Bosch Ronald J, Benson Constance A, Lederman Michael M
出版信息
J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):e60-3. doi: 10.1097/QAI.0b013e31827171d7.
Abstract
摘要
相似文献
1
Drug-resistant virus has reduced ability to induce immune activation.
J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):e60-3. doi: 10.1097/QAI.0b013e31827171d7.
2
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.
J Infect Dis. 2011 Apr 1;203(7):960-8. doi: 10.1093/infdis/jiq138.
3
Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection.
AIDS. 1999 Dec 3;13(17):2365-76. doi: 10.1097/00002030-199912030-00008.
4
Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.
AIDS Res Hum Retroviruses. 2017 Feb;33(2):133-142. doi: 10.1089/AID.2016.0108. Epub 2016 Oct 18.
5
Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection.
J Acquir Immune Defic Syndr. 2002 May 1;30(1):33-40. doi: 10.1097/00042560-200205010-00005.
6
Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy.
J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):153-60. doi: 10.1097/QAI.0000000000000286.
7
Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
J Med Virol. 2016 Aug;88(8):1347-56. doi: 10.1002/jmv.24475. Epub 2016 Jan 20.
8
Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection.
Clin Exp Immunol. 1994 Mar;95(3):436-41. doi: 10.1111/j.1365-2249.1994.tb07015.x.
9
CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus.
J Infect Dis. 2008 May 15;197(10):1402-7. doi: 10.1086/587696.
10
Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA.
AIDS Res Hum Retroviruses. 1999 Jul 20;15(11):963-72. doi: 10.1089/088922299310476.
引用本文的文献
1
Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.
J Virol. 2014 Aug;88(15):8629-39. doi: 10.1128/JVI.01257-14. Epub 2014 May 21.
本文引用的文献
1
Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.
AIDS. 2011 Nov 13;25(17):2123-31. doi: 10.1097/QAD.0b013e32834c4ac1.
2
Immune activation, CD4+ T cell counts, and viremia exhibit oscillatory patterns over time in patients with highly resistant HIV infection.
PLoS One. 2011;6(6):e21190. doi: 10.1371/journal.pone.0021190. Epub 2011 Jun 20.
3
Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity.
PLoS One. 2011 Jan 31;6(1):e14638. doi: 10.1371/journal.pone.0014638.
4
Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells.
PLoS Pathog. 2010 Nov 24;6(11):e1001213. doi: 10.1371/journal.ppat.1001213.
5
HIV infection, inflammation, immunosenescence, and aging.
Annu Rev Med. 2011;62:141-55. doi: 10.1146/annurev-med-042909-093756.
6
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
PLoS Med. 2008 Oct 21;5(10):e203. doi: 10.1371/journal.pmed.0050203.
7
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.
J Infect Dis. 2008 Jan 1;197(1):126-33. doi: 10.1086/524143.
8
A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164).
J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):418-25. doi: 10.1097/QAI.0b013e318061b611.
9
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
J Infect Dis. 2006 Nov 1;194(9):1309-18. doi: 10.1086/508289. Epub 2006 Sep 22.
10
Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study.
J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):169-78. doi: 10.1097/01.qai.0000242450.74779.ee.
Zotero 插件